📰Disease-modifying effect of efruxifermin in compensated cirrhosis due to MASH: To miss the forest for the tree(s)
👉Cirrhosis regression only partially captures the potential therapeutic benefit of disease-modifying drugs in phase 3
🖇️ for explanation: authors.elsevier.com/sd/article/S...
I am very sad. My mentor and friend, Jaume Bosch, just has passed away. Thanks for everything, I will miss you. I would always remember our last day together celebrating a journey we begin together @hospitalclinic.bsky.social @idibaps.bsky.social
Overview on published/presented data on MASH cirrhosis #LiverSky @bavenocoop.bsky.social
🖇️: authors.elsevier.com/sd/article/S...
🖤 With deep sorrow, we announce the passing of Prof. Dr. Jaime Bosch, President of the Baveno Cooperation.
A brilliant scientist, inspiring leader, and dear friend. His immense legacy in hepatology will endure.
Rest in peace, Jaime
Monitoring resmetirom by LSM - asking for the moon?
Oftentimes mentioned but even more often forgotten:
❗️Random variation of LSM by VCTE exceeds 25%
👉🔽 LSM >25% often by chance, same for 'unchanged' or increases
👉No substitute for clinical judgement
#LiverSky @georg-semmler.bsky.social
🔗👇
📰Disease-modifying effect of efruxifermin in compensated cirrhosis due to MASH: To miss the forest for the tree(s)
👉Cirrhosis regression only partially captures the potential therapeutic benefit of disease-modifying drugs in phase 3
🖇️ for explanation: authors.elsevier.com/sd/article/S...
